Income Statement Boston Scientific Corporation
Equities
BSX
US1011371077
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 92.70 USD | +0.18% |
|
-5.96% | +3.78% |
| 12-08 | Why the Fed's Next Move Matters More Than Markets Admit | |
| 12-08 | Analyst recommendations: 3M Company, Exxon Mobil, Mastercard, Netflix, Tesla… |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 9.91B | 11.89B | 12.68B | 14.24B | 16.75B | |||||
Total Revenues | 9.91B | 11.89B | 12.68B | 14.24B | 16.75B | |||||
Cost of Goods Sold, Total | 3.12B | 3.65B | 4B | 4.39B | 5.29B | |||||
Gross Profit | 6.79B | 8.24B | 8.68B | 9.85B | 11.46B | |||||
Selling General & Admin Expenses, Total | 3.74B | 4.29B | 4.52B | 5.19B | 5.98B | |||||
R&D Expenses | 1.14B | 1.2B | 1.32B | 1.41B | 1.62B | |||||
Amortization of Goodwill and Intangible Assets - (IS) | 789M | 741M | 803M | 828M | 856M | |||||
Other Operating Expenses, Total | 5.66B | 6.23B | 6.65B | 7.43B | 8.46B | |||||
Operating Income | 1.13B | 2.01B | 2.03B | 2.42B | 3B | |||||
Interest Expense, Total | -361M | -341M | -470M | -265M | -305M | |||||
Interest And Investment Income | 3M | 4M | 10M | 22M | 107M | |||||
Net Interest Expenses | -358M | -337M | -460M | -243M | -198M | |||||
Currency Exchange Gains (Loss) | -32M | -27M | -31M | -41M | -16M | |||||
Other Non Operating Income (Expenses) | 6M | -7M | -14M | -16M | -30M | |||||
EBT, Excl. Unusual Items | 745M | 1.64B | 1.53B | 2.12B | 2.76B | |||||
Restructuring Charges | -298M | -191M | -24M | -69M | -16M | |||||
Merger & Related Restructuring Charges | -58M | -34M | - | - | - | |||||
Impairment of Goodwill | -73M | - | - | - | - | |||||
Gain (Loss) On Sale Of Investments | 383M | 250M | -1M | -59M | -79M | |||||
Gain (Loss) On Sale Of Assets | - | 78M | -22M | - | - | |||||
Asset Writedown | -452M | -370M | -132M | -58M | -386M | |||||
Legal Settlements | -278M | -430M | -173M | 111M | - | |||||
Other Unusual Items | -49M | 136M | -35M | -58M | 5M | |||||
EBT, Incl. Unusual Items | -80M | 1.08B | 1.14B | 1.98B | 2.28B | |||||
Income Tax Expense | 2M | 36M | 443M | 393M | 436M | |||||
Earnings From Continuing Operations | -82M | 1.04B | 698M | 1.59B | 1.85B | |||||
Net Income to Company | -82M | 1.04B | 698M | 1.59B | 1.85B | |||||
Minority Interest | - | - | - | 1M | 8M | |||||
Net Income - (IS) | -82M | 1.04B | 698M | 1.59B | 1.85B | |||||
Preferred Dividend and Other Adjustments | 33M | 55M | 56M | 22M | 1M | |||||
Net Income to Common Incl Extra Items | -115M | 986M | 642M | 1.57B | 1.85B | |||||
Net Income to Common Excl. Extra Items | -115M | 986M | 642M | 1.57B | 1.85B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -0.08 | 0.69 | 0.45 | 1.08 | 1.26 | |||||
Basic EPS - Continuing Operations | -0.08 | 0.69 | 0.45 | 1.08 | 1.26 | |||||
Basic Weighted Average Shares Outstanding | 1.42B | 1.42B | 1.43B | 1.45B | 1.47B | |||||
Net EPS - Diluted | -0.08 | 0.69 | 0.45 | 1.07 | 1.25 | |||||
Diluted EPS - Continuing Operations | -0.08 | 0.69 | 0.45 | 1.07 | 1.25 | |||||
Diluted Weighted Average Shares Outstanding | 1.42B | 1.43B | 1.44B | 1.46B | 1.49B | |||||
Normalized Basic EPS | 0.33 | 0.72 | 0.67 | 0.91 | 1.18 | |||||
Normalized Diluted EPS | 0.33 | 0.71 | 0.66 | 0.9 | 1.17 | |||||
Payout Ratio | -34.15 | 5.28 | 7.88 | 1.76 | - | |||||
American Depositary Receipts Ratio (ADR) | 1 | 1 | 1 | 1 | 1 | |||||
Supplemental Items | ||||||||||
EBITDA | 2.25B | 3.1B | 3.17B | 3.61B | 4.27B | |||||
EBITA | 1.92B | 2.75B | 2.84B | 3.24B | 3.86B | |||||
EBIT | 1.13B | 2.01B | 2.03B | 2.42B | 3B | |||||
EBITDAR | 2.34B | 3.19B | 3.26B | 3.71B | 4.37B | |||||
Effective Tax Rate - (Ratio) | -2.5 | 3.34 | 38.83 | 19.81 | 19.11 | |||||
Current Domestic Taxes | -64M | 51M | 70M | 204M | 341M | |||||
Current Foreign Taxes | 151M | 127M | 381M | 116M | 184M | |||||
Total Current Taxes | 87M | 178M | 451M | 320M | 525M | |||||
Deferred Domestic Taxes | -32M | -259M | -124M | -104M | -183M | |||||
Deferred Foreign Taxes | -53M | 117M | 117M | 176M | 92M | |||||
Total Deferred Taxes | -85M | -142M | -7M | 72M | -91M | |||||
Normalized Net Income | 466M | 1.02B | 955M | 1.32B | 1.73B | |||||
Non-Cash Pension Expense | - | - | - | - | - | |||||
Supplemental Operating Expense Items | ||||||||||
Research And Development Expense From Footnotes | 1.14B | 1.2B | 1.32B | 1.41B | 1.62B | |||||
Net Rental Expense, Total | 92M | 90M | 91M | 96M | 98M | |||||
Imputed Operating Lease Interest Expense | 26.62M | 25.66M | 36.27M | 21.52M | 23M | |||||
Imputed Operating Lease Depreciation | 65.38M | 64.34M | 54.73M | 74.48M | 75M | |||||
Stock-Based Comp., COGS (Total) | 9M | 11M | 12M | 12M | 14M | |||||
Stock-Based Comp., R&D Exp. (Total) | 30M | 36M | 41M | 42M | 46M | |||||
Stock-Based Comp., SG&A Exp. (Total) | 130M | 147M | 167M | 179M | 206M | |||||
Stock-Based Comp., Other (Total) | 1M | - | - | - | - | |||||
Total Stock-Based Compensation | 170M | 194M | 220M | 233M | 266M |
- Stock Market
- Equities
- BSX Stock
- Financials Boston Scientific Corporation
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















